Total operating expenses 9,021 15,026 33,620 34,652
Loss from operations (6,560) (12,565) (23,770) (24,802)
Other income (expense)
Interest income 370 827 2,069 1,559
Interest expense (171) (258) (817) (994)
Other income (expense), net (1,795) (1,142) (851) (1,140)
Total other income (expense) (1,596) (573) 401 (575)
Net loss (8,156) (13,138) (23,369) (25,377)
Dividends and accretion to
redemption value of
redeemable convertible
preferred stock - 3,534 - -
Net loss attributable to
common stockholders $ (8,156) $ (9,604) $(23,369) $(25,377)
Basic and diluted net loss
per share attributable to
common stockholders* $ (0.52) $ (0.89) $ (1.49) $ (8.18)
Weighted average shares used
in the computation of basic
and diluted net loss per
share attributable to
common stockholders* 15,738,297 10,782,225 15,717,984 3,100,852
* Basic and diluted net loss per share attributable to common stockholders
and weighted average shares outstanding were impacted by the conversion
of preferred stock and issuance of common stock in connection with the
Axonyx merger.
'/>"/>SOURCE TorreyPines Therapeutics, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 Related biology technology :1.
TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia2.
TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference3.
TorreyPines Therapeutics Reports Third Quarter 2007 Results4.
TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference5.
TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference6.
TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease7.
TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference8.
TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference9.
Amsterdam Molecular Therapeutics to Appoint Alexander Ribbink to Supervisory Board10.
Blake M. Paterson MD, CEO and Co-founder of Alba Therapeutics, Wins Greater Baltimore Committee 2008 Leadership in Bioscience Award11.
Cell Therapeutics, Inc. (CTI) Invest Northwest Presentation to be Webcast